Skip to main content

Table 4 Primary and other ophthalmological endpoints# (ophthalmological population)

From: Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study

 

BGF MDI 320/18/9.6 μg (N = 132)

BFF MDI 320/9.6 μg (N = 54)

GFF MDI 18/9.6 μg (N = 125)

LOCS III P score

n

218

98

184

 Baseline (mean [SD])

0.381 (0.880)

0.397 (0.650)

0.308 (0.567)

 Change from baseline to Week 52 (primary ophthalmological endpoint)

  LSM

0.153

0.022

0.026

  95% CI

(0.079, 0.227)

(−0.090, 0.135)

(−0.055, 0.106)

  LSM difference between treatments

   Versus GFF MDI 18/9.6 μg

    LSM

0.127

−0.003

NA

    95% CI

(0.017, 0.237)

(− 0.142, 0.135)

 

   Versus BFF MDI 320/9.6 μg§

    LSM

0.130

NA

Shown above

    95% CI

(−0.004, 0.265)

  

LOCS III NO score

n

220

98

187

 Baseline (mean [SD])

2.447 (1.082)

2.336 (0.886)

2.309 (1.060)

 Change from baseline to Week 52

  LSM

0.255 (0.170, 0.340)

0.186 (0.059, 0.314)

0.047 (−0.045, 0.138)

  95% CI

  LSM difference between treatments§

   Versus GFF MDI 18/9.6 μg

    LSM

0.208

0.140

NA

    95% CI

(0.084, 0.333)

(−0.017, 0.297)

 

   Versus BFF MDI 320/9.6 μg

    LSM

0.069

NA

Shown above

    95% CI

(−0.084, 0.222)

  

LOCS III NC score

n

219

98

187

 Baseline (mean [SD])

2.290 (1.137)

2.287 (0.951)

2.178 (0.858)

 Change from baseline to Week 52

  LSM

0.130

0.142

0.163

  95% CI

(0.050, 0.209)

(0.022, 0.263)

(0.077, 0.248)

  LSM difference between treatments§

   Versus GFF MDI 18/9.6 μg

    LSM

−0.033

−0.021

NA

    95% CI

(−0.150, 0.084)

(−0.169, 0.128)

 

   Versus BFF MDI 320/9.6 μg

    LSM

−0.013

NA

Shown above

    95% CI

(−0.157, 0.132)

  

LOCS III C score

n

218

98

187

 Baseline (mean [SD])

0.832 (1.189)

0.801 (0.976)

0.727 (1.060)

 Change from baseline to Week 52

  LSM

0.105 (0.022, 0.187)

0.170 (0.047, 0.294)

0.067 (−0.022, 0.155)

  95% CI

  LSM difference between treatments§

   Versus GFF MDI 18/9.6 μg

    LSM

0.038

0.103

NA

    95% CI

(−0.083, 0.159)

(−0.049, 0.256)

 

   Versus BFF MDI 320/9.6 μg

    LSM

−0.065

NA

Shown above

    95% CI

(−0.214, 0.083)

  

IOP, mmHg

n

228

100

203

 Baseline (mean [SD])

14.482 (2.908)

15.490 (2.740)

14.978 (2.971)

 Change from baseline to Week 52

  LSM

0.670

0.178

0.680

  95% CI

(0.330, 1.010)

(−0.339, 0.696)

(0.321, 1.039)

  LSM difference between treatments§

   Versus GFF MDI 18/9.6 μg

    LSM

−0.010

−0.502

NA

    95% CI

(−0.505, 0.486)

(−1.131, 0.128)

 

   Versus BFF MDI 320/9.6 μg

    LSM

0.492

NA

Shown above

    95% CI

(−0.129, 1.113)

  
  1. BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, C Cortical cataract, CI Confidence interval, GFF Glycopyrrolate/formoterol fumarate, IOP Intraocular pressure, LOCS III Lens opacities classification system III, LSM Least squares mean, MDI Metered dose inhaler, NA Not applicable, NC Nuclear color, NO Nuclear opalescence, P Posterior subcapsular cataract, SD Standard deviation. #: data presented are across eyes (irrespective of person) such that n = total number of eyes assessed, : non-inferiority was declared if the upper confidence bound for the treatment difference was <0.5, §: not a pre-specified non-inferiority comparison